Mynvax

Mynvax is a clinical-stage vaccine biotechnology company based in Bengaluru, India, founded in 2017 with the stated vision of developing novel, improved, recombinant, thermostable vaccines to protect against respiratory viral infections. The company is built around a platform technology for protein stabilization, through which it engineers stabilizing mutations in protein antigens to enhance the elicitation of neutralizing antibody responses in vaccine formulations. This platform underpins both its influenza and SARS-CoV-2 programs. Mynvax's influenza vaccine candidates include microbially expressed stem regions of the influenza hemagglutinin (HA) protein, which, in combination with recombinant HA, are intended to elicit an improved breadth of protection compared with existing influenza vaccines. Separately, the company has developed thermotolerant, efficacious vaccines for protection against SARS-CoV-2 and its evolving variants. Mynvax has stated that it successfully demonstrated its vaccine design capabilities by quickly developing a thermotolerant COVID-19 vaccine formulation that is efficacious against earlier and current viral variants and accessible to low- and lower-middle-income countries. Mynvax was named as one of seven Indian vaccine companies working on developing vaccines for COVID-19. It operates as a biotech start-up incubated at the Indian Institute of Science (IISc), with deep collaboration with laboratories at IISc, and has received financial support from SID, the incubation centre of the Indian Institute of Science, from BIRAC and the Department of Biotechnology, Government of India, and from various early-stage Indian and global investors. Some of its programs are grant funded by leading Indian government funding agencies. The company has initiated commercial development partnerships with vaccine manufacturers and has built commercial relationships with CDMOs and large vaccine manufacturers in India and overseas. It has also developed multiple collaborations in India and overseas with leading researchers in vaccine design, formulation expertise, and clinical development. Using its novel intellectual property, patents, and scientific know-how in protein stabilization and design, Mynvax aims to deploy its novel vaccines for improved protection against respiratory viral diseases. It has a young team of highly qualified scientists.

Mynvax was founded in 2017 as a clinical-stage vaccine biotechnology company with the singular vision of developing novel, improved, recombinant, thermostable vaccines to protect against respiratory viral infections. It is based in Bengaluru, India, and operates as a biotech start-up incubated at the Indian Institute of Science (IISc). The company has a young team of highly qualified scientists. Mynvax built its scientific foundation on a platform technology for protein stabilization. Using this platform, the company engineers stabilizing mutations in protein antigens to enhance the elicitation of neutralizing antibody responses in vaccine formulations. This approach is applied across its respiratory virus vaccine programs. In influenza, Mynvax's vaccine candidates include microbially expressed stem regions of the influenza hemagglutinin (HA) protein, which, in combination with recombinant HA, are designed to elicit an improved breadth of protection compared to existing influenza vaccines. During the COVID-19 pandemic, Mynvax was named as one of seven Indian vaccine companies working on developing vaccines for COVID-19. The company successfully demonstrated its vaccine design capabilities by quickly developing a thermotolerant COVID-19 vaccine formulation that is efficacious against earlier and current viral variants and accessible to low- and lower-middle-income countries. It also developed thermo-tolerant, efficacious vaccines for protection against SARS-CoV-2 and its evolving variants. Mynvax has received financial support from SID, the incubation centre of the Indian Institute of Science, from BIRAC and the Department of Biotechnology, Government of India, and from various early-stage Indian and global investors. Some of its programs are grant funded by leading Indian government funding agencies. The company has developed multiple collaborations in India and overseas with leading researchers in vaccine design, formulation expertise, and clinical development, and has deep collaboration with laboratories at IISc. It has also built commercial relationships with CDMOs and large vaccine manufacturers, and has initiated commercial development partnerships with vaccine manufacturers. Using its novel intellectual property, patents, and scientific know-how in protein stabilization and design, Mynvax aims to deploy its novel vaccines for improved protection against respiratory viral diseases.

• 2017

  Mynvax founded as a clinical-stage vaccine biotechnology company.

• Named as one of seven Indian vaccine companies working on developing vaccines for COVID-19.

• Developed a thermotolerant COVID-19 vaccine formulation efficacious against earlier and current viral variants.

• Initiated commercial development partnerships with vaccine manufacturers.

Clinical-stage vaccine biotechnology company developing novel, thermostable recombinant protein subunit vaccines for respiratory viral infections, with a focus on accessibility for low- and lower-middle-income countries.

• Thermotolerant COVID-19 vaccine formulation

  A thermotolerant COVID-19 vaccine formulation efficacious against earlier and current viral variants and accessible to low- and lower-middle-income countries.

• Influenza vaccine candidates

  Candidates including microbially expressed stem regions of the influenza hemagglutinin (HA) protein, which in combination with recombinant HA elicit improved breadth of protection compared to existing influenza vaccines.

• Protein stabilization platform technology

  Platform used to engineer stabilizing mutations in protein antigens to enhance elicitation of neutralizing antibody responses in vaccine formulations.

1. 1Mynvaxmynvax.com
2. 2Mynvax: About Usmynvax.com
3. 3Mynvax (India)wikidata.org